7 Frame

This project is supported through Coordination Theme 1 (Health) of the European Community's FP7. Grant agreement number HEALTH-F2-2008-00

EU Flag

Disclaimer

Work Package 4

logoWP 4: Biochemical markers (BM) of OA progression and incidence

Participants:

Synarc, KCL, LUMC, Erasmus

Objectives:

  1. To examine the value of established and novel biochemical markers (BM) in the pipeline for joint tissue metabolism to predict OA progression.
  2. To identify genes which contribute to systemic BM levels.
  3. To identify a panel of few BMs to be included in the risk prediction model described in WP-8.

Status:

One of the objectives of WP4 (biochemical markers) was to measure urinary levels of CTX-II (U-CTX-II) and serum levels of COMP (S-COMP) in cohorts of WP1. Measurements of U-CTX-II and S-COMP levels have been performed on 1059 patients of Twin UK study and on 778 patients of Chingford study. U-CTX-II and S-COMP means obtained in these two populations are very similar with the data obtained in our laboratory and with the data previously published (Reijman et al. Arthritis and Rheumatism, 2004; Sharif et al. Arthritis and Rheumatism, 2004). The evaluation of new pipeline biochemical markers is currently in progress.

Publications:

  • Association of biomarkers with pre-radiographically defined and radiographically defined knee osteoarthritis in a population-based study. Cibere J, Zhang H, Garnero P, Poole AR, Lobanok T, Saxne T, Kraus VB, Way A, Thorne A, Wong H, Singer J, Kopec J, Guermazi A, Peterfy C, Nicolaou S, Munk PL, Esdaile JM.
  • Biochemical markers of bone turnover and their association with bone marrow lesions. Hunter DJ, Lavalley M, Li J, Bauer DC, Nevitt M, DeGroot J, Poole R, Eyre D, Guermazi A, Gale D, Totterman S, Felson DT. Arthritis Res Ther. 08;10(4):R102. Epub 2008 Aug 29.
  • Nitrated type III collagen as a biological marker of nitric oxide-mediated synovial tissue metabolism in osteoarthritis. Richardot P, Charni-Ben Tabassi N, Toh L, Marotte H, Bay-Jensen AC, Miossec P, Garnero P. Osteoarthritis Cartilage. 2009 May 12.
  • Can biochemical markers serve as surrogates for imaging in knee osteoarthritis? Davis CR, Karl J, Granell R, Kirwan JR, Fasham J, Johansen J, Garnero P, Sharif M. Arthritis Rheum. 2007 Dec;56(12):4038-47.
  • Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. Garnero P, Aronstein WS, Cohen SB, Conaghan PG, Cline GA, Christiansen C, Beary JF, Meyer JM, Bingham CO 3rd. Osteoarthritis Cartilage. 2008 Jun;16(6):660-6. Epub 2007 Nov 13.
  • Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI. Dam EB, Byrjalsen I, Karsdal MA, Qvist P, Christiansen C. Osteoarthritis Cartilage. 2009 Mar;17(3):384-9. Epub 2008 Sep 3.